A detailed history of Captrust Financial Advisors transactions in Insmed Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 6,280 shares of INSM stock, worth $442,928. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,280
Previous 4,456 40.93%
Holding current value
$442,928
Previous $298,000 53.69%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$62.0 - $79.01 $113,088 - $144,114
1,824 Added 40.93%
6,280 $458,000
Q2 2024

Aug 14, 2024

BUY
$22.0 - $69.71 $98,032 - $310,627
4,456 New
4,456 $298,000
Q4 2023

Feb 14, 2024

SELL
$23.42 - $31.74 $347,669 - $471,180
-14,845 Reduced 33.49%
29,481 $913,000
Q3 2023

Nov 14, 2023

BUY
$19.86 - $26.93 $90,005 - $122,046
4,532 Added 11.39%
44,326 $1.12 Million
Q2 2023

Aug 14, 2023

BUY
$16.44 - $21.1 $654,213 - $839,653
39,794 New
39,794 $839,000
Q2 2022

Aug 16, 2022

SELL
$17.07 - $25.71 $853 - $1,285
-50 Reduced 25.77%
144 $3,000
Q1 2022

May 16, 2022

SELL
$20.42 - $28.13 $408 - $562
-20 Reduced 9.35%
194 $5,000
Q4 2021

Feb 14, 2022

BUY
$25.89 - $33.45 $5,126 - $6,623
198 Added 1237.5%
214 $6,000
Q3 2021

Nov 16, 2021

SELL
$22.46 - $29.47 $5,435 - $7,131
-242 Reduced 93.8%
16 $0
Q2 2021

Aug 16, 2021

BUY
$24.17 - $36.01 $5,679 - $8,462
235 Added 1021.74%
258 $7,000
Q1 2021

May 17, 2021

BUY
$32.28 - $44.3 $742 - $1,018
23 New
23 $1,000
Q3 2020

Nov 17, 2020

SELL
$26.0 - $34.5 $10,400 - $13,800
-400 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$14.11 - $29.42 $5,644 - $11,768
400 New
400 $12,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $9.56B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.